期刊
JOURNAL OF MEDICAL VIROLOGY
卷 93, 期 1, 页码 300-310出版社
WILEY
DOI: 10.1002/jmv.26264
关键词
coronavirus; COVID-19; drug target; RdRp; SARS-CoV-2
类别
资金
- National Science and Technology Major Project [2018ZX09711001]
- Shandong Provincial Natural Science Foundation [ZR2019MH078]
The global pandemic caused by the novel coronavirus has infected millions of people and urgently requires effective therapeutic measures. RdRp has been identified as a potential target for antiviral strategies, with studies showing its high conservation across different coronaviruses.
The global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), named coronavirus disease 2019, has infected more than 8.9 million people worldwide. This calls for urgent effective therapeutic measures. RNA-dependent RNA polymerase (RdRp) activity in viral transcription and replication has been recognized as an attractive target to design novel antiviral strategies. Although SARS-CoV-2 shares less genetic similarity with SARS-CoV (similar to 79%) and Middle East respiratory syndrome coronavirus (similar to 50%), the respective RdRps of the three coronaviruses are highly conserved, suggesting that RdRp is a good broad-spectrum antiviral target for coronaviruses. In this review, we discuss the antiviral potential of RdRp inhibitors (mainly nucleoside analogs) with an aim to provide a comprehensive account of drug discovery on SARS-CoV-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据